Shenzhen Salubris Pharmaceuticals Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 4,087

Employees

  • Stock Symbol
  • 002294

Stock Symbol

  • Investments
  • 20

  • Share Price
  • $3.95
  • (As of Thursday Closing)

Shenzhen Salubris Pharmaceuticals General Information

Description

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.

Contact Information

Formerly Known As
Shenzhen Sinopharm Biomedical Engineering Co., Ltd.
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 37th Floor, Block B, NEO Greenview Plaza
  • Number 6009 Shennan Avenue, Futian District
  • Shenzhen, Guangdong
  • China
+86 0755
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
SHE
Vertical(s)
Corporate Office
  • 37th Floor, Block B, NEO Greenview Plaza
  • Number 6009 Shennan Avenue, Futian District
  • Shenzhen, Guangdong
  • China
+86 0755

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shenzhen Salubris Pharmaceuticals Stock Performance

As of 19-Nov-2026, Shenzhen Salubris Pharmaceuticals’s stock price is $3.95. Its current market cap is $4.41B with 1.11B shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.95 $4.02 $3.88 - $10.33 $4.41B 1.11B 12M $0.09

Shenzhen Salubris Pharmaceuticals Financials Summary

As of 30-Sep-2026, Shenzhen Salubris Pharmaceuticals has a trailing 12-month revenue of $704M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 5,027,095 7,732,738 4,507,137 4,876,058
Revenue 704,245 605,266 559,160 475,675
EBITDA 99,355 144,991 136,278 132,312
Net Income 103,733 90,596 83,837 81,990
Total Assets 1,675,569 1,614,733 1,433,625 1,325,603
Total Debt 143,961 100,913 18,339 8,953
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shenzhen Salubris Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shenzhen Salubris Pharmaceuticals‘s full profile, request access.

Request a free trial

Shenzhen Salubris Pharmaceuticals Patents

Shenzhen Salubris Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026228703-A1 Α4β7 integrin compound, and preparation method therefor and use thereof Pending 30-Apr-2025
WO-2026228618-A1 Amylin receptor agonist, and preparation method therefor and use thereof Pending 28-Apr-2025
WO-2026228543-A1 Recombinant fusion protein having multiple activities and use thereof Pending 27-Apr-2025
WO-2026223737-A1 Bicyclic substituted compound and use thereof in apj receptor-related diseases Pending 24-Apr-2025
WO-2026219222-A1 Pcsk9 and lpa dual-targeting compound and use thereof Pending 16-Apr-2025
To view Shenzhen Salubris Pharmaceuticals’s complete patent history, request access »

Shenzhen Salubris Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shenzhen Salubris Pharmaceuticals Investments & Acquisitions (20)

Shenzhen Salubris Pharmaceuticals’s most recent deal was a Later Stage VC with Precision Scientific (China) for . The deal was made on 09-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Precision Scientific (China) 09-Dec-2025 Later Stage VC Laboratory Services (Healthcare)
Precision Scientific (China) 25-Nov-2024 Later Stage VC Laboratory Services (Healthcare)
Precision Scientific (China) 21-Feb-2024 Later Stage VC Laboratory Services (Healthcare)
Precision Scientific (China) 25-Jun-2023 Later Stage VC Laboratory Services (Healthcare)
Adicon Clinical Laboratory 19-Jun-2023 IPO Laboratory Services (Healthcare)
You’re viewing 5 of 20 investments and acquisitions. Get the full list »

Shenzhen Salubris Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

39.23 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Shenzhen Salubris Pharmaceuticals’s complete esg history, request access »

Shenzhen Salubris Pharmaceuticals Exits (3)

Shenzhen Salubris Pharmaceuticals’s most recent exit was on 12-Feb-2019 from Viracta Therapeutics. The exit was categorized as with 5 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Viracta Therapeutics 12-Feb-2019 Completed
  • 5 buyers
MedAlliance (Drug Delivery) 21-May-2018 Completed
Go Therapeutics 08-Aug-2017 Early Stage VC Completed
To view Shenzhen Salubris Pharmaceuticals’s complete exits history, request access »

Shenzhen Salubris Pharmaceuticals Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Salubris Biomedical Engineering Shenzhen, China 2009
Jinkai Biotechnology Chengdu, China 2008

Shenzhen Salubris Pharmaceuticals FAQs

  • When was Shenzhen Salubris Pharmaceuticals founded?

    Shenzhen Salubris Pharmaceuticals was founded in 1998.

  • Where is Shenzhen Salubris Pharmaceuticals headquartered?

    Shenzhen Salubris Pharmaceuticals is headquartered in Shenzhen, China.

  • What is the size of Shenzhen Salubris Pharmaceuticals?

    Shenzhen Salubris Pharmaceuticals has 4,087 total employees.

  • What industry is Shenzhen Salubris Pharmaceuticals in?

    Shenzhen Salubris Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Shenzhen Salubris Pharmaceuticals a private or public company?

    Shenzhen Salubris Pharmaceuticals is a Public company.

  • What is Shenzhen Salubris Pharmaceuticals’s stock symbol?

    The ticker symbol for Shenzhen Salubris Pharmaceuticals is 002294.

  • What is the current stock price of Shenzhen Salubris Pharmaceuticals?

    As of 19-Nov-2026 the stock price of Shenzhen Salubris Pharmaceuticals is $3.95.

  • What is the current market cap of Shenzhen Salubris Pharmaceuticals?

    The current market capitalization of Shenzhen Salubris Pharmaceuticals is $4.41B.

  • What is Shenzhen Salubris Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Shenzhen Salubris Pharmaceuticals is $704M.

  • What is Shenzhen Salubris Pharmaceuticals’s annual earnings per share (EPS)?

    Shenzhen Salubris Pharmaceuticals’s EPS for 12 months was $0.09.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process